Broken promise doctrine in Canada poses questions for courts
The rejection of the promise doctrine has brought Canada into line with other countries and been welcomed by pharmaceutical companies. It also raises questions such as how courts will determine the “subject matter of the invention” and how the enhanced disclosure requirement will be resolved
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
